education
Hosted by ACE Oncology · education · EN-US · 50 episodes
The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
20%
Guest openness
Selective
Sign up to generate a grounded pitch for ACE OncoCast.
Signup to Generate a PitchThe official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.
ACE OncoCast is hosted by ACE Oncology. The show has published 50 episodes to date.
Recent episodes include "Expert Interview of Dr Guerrero: Optimal Management for NMIBC and MIBC Patients from a Surgical Perspective" (15 November 2025, 17 minutes), "Expert Interview of Dr Enrique Grande: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer" (15 November 2025, 20 minutes), and "Expert Interview of Dr Carballo: The Role of Radiotherapy for MIBC Patients" (15 November 2025, 5 minutes).
ACE OncoCast publishes roughly irregularly, with episodes averaging 17 minutes across 50 episodes.
Booking probability for ACE OncoCast is 20%, and the host is rated Selective on guests. ACE OncoCast requires a Pod Score of 80 or higher. ACE OncoCast's contact route on record: public web form.
The strongest fits for ACE OncoCast are Health & Wellness Services. ACE OncoCast has an education audience.
ACE Oncology hosts ACE OncoCast, an education show with 50 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #3
<p><b>Félix Guerrero-Ramos, MD, PhD, FEBU<br/></b>Hospital Doce de Octubre<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the...
Episode #1
<p><b>Enrique Grande, MD, MSc, PhD</b> <br/>Quirónsalud Madrid<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of...
Episode #4
<p><b>Natalia Carballo, MD<br/></b>Sanitas Hospitals/Atrys Health<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition...
Episode #2
<p><b>Francisco X. Real, MD, PhD<br/></b>National Cancer Research Center<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the...
Episode #2
<p><b>Félix Guerrero-Ramos, MD, PhD, FEBU<br/></b>Hospital Doce de Octubre<br/>Madrid, Spain<br/><br/>The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the...
Episode #2
<p><b>Natalia Carballo, MD<br/></b>MD Anderson Cancer Center Madrid<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of...
Episode #3
<p><b>Enrique Grande, MD, MSc, PhD</b><br/>MD Anderson Cancer Center Madrid<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the...
Episode #1
<p><b>Francisco X. Real, MD, PhD<br/></b>National Cancer Research Center<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the...
Episode #1
<p><b>Episode 1: <br/>Opening & Keynote Speech: Second-line and salvage treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC)<br/></b>Philippe Barthélémy, MD...
Episode #2
<p><b>Episode 2:</b> <br/><b>Case 1: First-line treatment with maintenance immunotherapy for a platinum-eligible patient <br/>Case 2: First-line treatment with mono-immunotherapy for a cisplatin-ineligible...
Episode #2
<p><b>Episode 2: </b><br/><b>Case 1: Second-line and salvage treatment options after maintenance immunotherapy <br/>Case 2: Second-line and salvage treatment options after platinum-based chemotherapy<br/></b>Kate Smith...
ACE OncoCast
<p><b>Episode 1: <br/>Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC)<br/></b>Enrique Grande, MD, MSc, PhD<br/><br/>The...
Episode #3
<p><b>Episode 3: <br/>Panel Discussion & Pearls for Practice<br/></b>Fernando Maluf, MD, PhD, Enrique Grande, MD, MSc, PhD and Joachim Chan, BSc, MBBS, MRCP, FRCR, MD<br/><br/>The therapeutic landscape of unresectable...
Episode #3
<p><b>Episode 3:</b><br/><b>Panel Discussion & Pearls for Practice<br/></b>Aristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhD<br/><br/>The increasing availability of treatment...
Episode #2
<p>The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug...
Episode #3
<p>The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug...
Episode #1
<p>The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug...
Episode #4
<p>The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug...
Episode #1
<p>About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical...
Episode #2
<p>Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist...
Recent guests on ACE OncoCast. Study who booked and why before you pitch.
PitchCentric classifies ACE OncoCast under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ